These cells are characterized by the production of IL-10 immunosuppressive cytokine and upregulation of immunoregulatory mediators programmed death ligand-1 (PD-L1)/PD-L2 (27–30), which are being actively evaluated as targets for cancer immunotherapy (31). The gene discussed is IL10; the disease is cancer.